Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls.

Macarulla T, Montagut C, Sánchez-Martin FJ, Granja M, Verdaguer H, Sastre J, Tabernero J.

Expert Opin Biol Ther. 2019 Oct 16:1-8. doi: 10.1080/14712598.2020.1677603. [Epub ahead of print]

PMID:
31608707
2.

Dynamic Treatment Stratification Using ctDNA.

Vidal J, Taus A, Montagut C.

Recent Results Cancer Res. 2020;215:263-273. doi: 10.1007/978-3-030-26439-0_14.

PMID:
31605234
3.

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).

Bendell JC, Sauri T, Gracián AC, Alvarez R, López-López C, García-Alfonso P, Hussein M, Miron ML, Cervantes A, Montagut C, Vivas CS, Bessudo A, Plezia P, Moons V, Andel J, Bennouna J, van der Westhuizen A, Samuel L, Rossomanno S, Boetsch C, Lahr A, Franjkovic I, Heil F, Lechner K, Krieter O, Hurwitz H; McCAVE Study Group.

Oncologist. 2019 Sep 30. pii: theoncologist.2019-0291. doi: 10.1634/theoncologist.2019-0291. [Epub ahead of print]

PMID:
31570519
4.

HER-family ligands promote acquired resistance to trastuzumab in gastric cancer.

Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S, Gaye É, Dalmases A, Clavé S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C.

Mol Cancer Ther. 2019 Sep 4. pii: molcanther.0455.2019. doi: 10.1158/1535-7163.MCT-19-0455. [Epub ahead of print]

PMID:
31484705
5.

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.

Fernández-Martos C, Pericay C, Losa F, García-Carbonero R, Layos L, Rodríguez-Salas N, Martin-Richard M, Alonso-Orduña V, Vera R, Gallego J, Capdevila J, Salud A, Nogué M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.2294. [Epub ahead of print]

PMID:
31465088
6.

ctDNA to detect minimal residual disease in pancreatic cancer: moving into clinical trials.

Montagut C, Vidal J.

Ann Oncol. 2019 Sep 1;30(9):1410-1413. doi: 10.1093/annonc/mdz236. No abstract available.

PMID:
31418008
7.

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.

Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P.

Drugs. 2019 Sep;79(13):1375-1394. doi: 10.1007/s40265-019-01165-2. Review.

8.

IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.

Colomer C, Margalef P, Villanueva A, Vert A, Pecharroman I, Solé L, González-Farré M, Alonso J, Montagut C, Martinez-Iniesta M, Bertran J, Borràs E, Iglesias M, Sabidó E, Bigas A, Boulton SJ, Espinosa L.

Mol Cell. 2019 Aug 22;75(4):669-682.e5. doi: 10.1016/j.molcel.2019.05.036. Epub 2019 Jul 10.

9.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J.

J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.

PMID:
30892987
10.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C.

Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005.

PMID:
30689692
11.

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.

García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, Camps C, Jantus-Lewintre E, López R, Muinelo-Romay L, Montagut C, Antón A, López G, Díaz-Rubio E, Rojo F, Vivancos A.

Br J Cancer. 2018 Dec;119(12):1464-1470. doi: 10.1038/s41416-018-0293-5. Epub 2018 Nov 23.

12.

KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer.

Montagut C, Vidal J, Visa L.

Ann Oncol. 2018 Dec 1;29(12):2280-2282. doi: 10.1093/annonc/mdy484. No abstract available.

PMID:
30423018
13.

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).

García-Alfonso P, Benavides M, Falcó E, Muñoz A, Gómez A, Sastre J, Rivera F, Montagut C, Salgado M, López-Ladrón A, López R, Ruiz de Mena I, Durán G, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

Oncologist. 2018 Nov;23(11):1271-e128. doi: 10.1634/theoncologist.2018-0316. Epub 2018 Aug 17.

14.

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.

Prieto-Potin I, Montagut C, Bellosillo B, Evans M, Smith M, Melchior L, Reiltin W, Bennett M, Pennati V, Castiglione F, Bürrig KF, Cooper U, Dockhorn-Dworniczak B, Rossenbach C, Luna-Aguirre CM, Barrera-Saldaña HA, Machado JC, Costa JL, Yacobi R, Tabibian-Keissar H, Buglioni S, Ronchetti L, Douglas-Berger L, Dubbink HJ, Alorini M, Sabourin JC, Rojo F.

J Mol Diagn. 2018 Sep;20(5):664-676. doi: 10.1016/j.jmoldx.2018.05.008. Epub 2018 Jun 26.

PMID:
29959022
15.

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.

Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D.

ESMO Open. 2018 May 5;3(4):e000353. doi: 10.1136/esmoopen-2018-000353. eCollection 2018. Review.

16.

Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?

Montagut C, Tsui DW, Diaz LA Jr.

Ann Oncol. 2018 May 1;29(5):1083-1084. doi: 10.1093/annonc/mdy091. No abstract available.

PMID:
29554200
17.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.

Gonzalez-Cao M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, Molina-Vila MÁ, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Muñoz E, Rodriguez-Abreu D, Perez E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R; Spanish Melanoma Group.

Melanoma Res. 2018 Jun;28(3):195-203. doi: 10.1097/CMR.0000000000000432.

PMID:
29481492
18.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12. Erratum in: JAMA Oncol. 2019 May 1;5(5):745.

19.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.

Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E.

Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737.

PMID:
29145602
20.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R.

Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16.

21.

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.

Patel UB, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, Salud A, Isabel-Gil M, Montagut C, Maurel J, Ramón-Ayuso J, Martin N, Estevan R, Fernandez-Martos C.

Ann Oncol. 2017 Feb 1;28(2):344-353. doi: 10.1093/annonc/mdw616.

PMID:
28426108
22.

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.

Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, Vidal Y, Candamio S, Vázquez F, Ruiz J, Guix M, Visa L, Sikri V, Albanell J, Bellosillo B, López R, Montagut C.

Ann Oncol. 2017 Jun 1;28(6):1325-1332. doi: 10.1093/annonc/mdx125.

23.

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.

Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A.

Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.

24.

Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.

Brammeld JS, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A, Bellosillo B, Robles-Espinoza CD, Price S, Barthorpe S, Tarpey P, Alifrangis C, Bignell G, Vidal J, Young J, Stebbings L, Beal K, Stratton MR, Saez-Rodriguez J, Garnett M, Montagut C, Iorio F, McDermott U.

Genome Res. 2017 Apr;27(4):613-625. doi: 10.1101/gr.213546.116. Epub 2017 Feb 8.

25.

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

González-Cao M, Arance A, Piulats JM, Marquez-Rodas I, Manzano JL, Berrocal A, Crespo G, Rodriguez D, Perez-Ruiz E, Berciano M, Soria A, Castano AG, Espinosa E, Montagut C, Alonso L, Puertolas T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P, Barron F, Martin-Algarra S; Spanish Melanoma Group.

Clin Transl Oncol. 2017 Jun;19(6):761-768. doi: 10.1007/s12094-016-1602-1. Epub 2017 Jan 4.

PMID:
28054320
26.

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A.

Nat Commun. 2016 Dec 8;7:13665. doi: 10.1038/ncomms13665.

27.

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.

Marzi L, Combes E, Vié N, Ayrolles-Torro A, Tosi D, Desigaud D, Perez-Gracia E, Larbouret C, Montagut C, Iglesias M, Jarlier M, Denis V, Linares LK, Lam EW, Martineau P, Del Rio M, Gongora C.

Br J Cancer. 2016 Nov 8;115(10):1223-1233. doi: 10.1038/bjc.2016.313. Epub 2016 Sep 29.

28.

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.

Solassol J, Vendrell J, Märkl B, Haas C, Bellosillo B, Montagut C, Smith M, O'Sullivan B, D'Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M, Mescoli C, Collin C, Pagès JC, Sillekens P.

PLoS One. 2016 Sep 29;11(9):e0163444. doi: 10.1371/journal.pone.0163444. eCollection 2016.

29.

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.

Casadevall D, Vidal J, Gallardo F, Zuccarino F, Arumí-Uría M, Dalmases A, Bellosillo B, Montagut C.

J Med Case Rep. 2016 Jun 2;10(1):158. doi: 10.1186/s13256-016-0953-0.

30.

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R.

Mol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.

31.

Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial).

Petty R, Anthoney A, Metges JP, Alsina M, Gonçalves A, Brown J, Montagut C, Gunzer K, Laus G, Iglesias Dios JL, Miguel-Lillo B, Bohan P, Salazar R.

Cancer Chemother Pharmacol. 2016 Apr;77(4):819-27. doi: 10.1007/s00280-016-2991-0. Epub 2016 Mar 10.

PMID:
26964995
32.

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.

Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17.

33.

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A.

Sci Transl Med. 2016 Feb 3;8(324):324ra14. doi: 10.1126/scitranslmed.aad5640.

34.

Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.

Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragón E, Micalessi I, Frans J, Noten V, Bourgain C, Vriesema R, van der Geize R, Cokelaere K, Vercooren N, Crul K, Rüdiger T, Buchmüller D, Reijans M, Jans C.

Exp Mol Pathol. 2015 Dec;99(3):485-91. doi: 10.1016/j.yexmp.2015.09.004. Epub 2015 Sep 25.

PMID:
26407762
35.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827b. No abstract available.

PMID:
26151329
36.

Hypersensitivity reaction caused by folinic acid administration: a case report and literature review.

Florit-Sureda M, Conde-Estévez D, Vidal J, Montagut C.

J Chemother. 2016 Dec;28(6):500-505. Epub 2016 Apr 25. Review.

PMID:
26042586
37.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Erratum in: Nat Med. 2015 Jul;21(7):doi:10.1038/nm0715-827b. Erratum in: Nat Med. 2015 Jul;21(7):827.

38.

Liquid biopsies to evaluate early therapeutic response in colorectal cancer.

Montagut C, Siravegna G, Bardelli A.

Ann Oncol. 2015 Aug;26(8):1525-7. doi: 10.1093/annonc/mdv228. Epub 2015 May 12. No abstract available.

PMID:
25969369
39.

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†.

Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, Safont MJ, Salud A, Vera R, Massuti B, Escudero P, Alonso V, Bosch C, Martin M, Minsky BD.

Ann Oncol. 2015 Aug;26(8):1722-8. doi: 10.1093/annonc/mdv223. Epub 2015 May 8.

PMID:
25957330
40.

BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent.

Margalef P, Colomer C, Villanueva A, Montagut C, Iglesias M, Bellosillo B, Salazar R, Martínez-Iniesta M, Bigas A, Espinosa L.

Sci Signal. 2015 Apr 21;8(373):ra38. doi: 10.1126/scisignal.2005886.

PMID:
25900832
41.

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C.

Clin Cancer Res. 2015 May 1;21(9):2157-66. doi: 10.1158/1078-0432.CCR-14-2821. Epub 2015 Jan 26.

42.

Incidental focal uptake in colorectal location on oncologic ¹⁸FDG PET and PET/CT studies: histopathological findings and clinical significances.

Fuertes J, Montagut C, Bullich S, Coma MI, Mestre-Fusco A, Suárez-Piñera M, Trampal C, Bellmunt J.

Rev Esp Med Nucl Imagen Mol. 2015 Mar-Apr;34(2):95-101. doi: 10.1016/j.remn.2014.07.008. Epub 2014 Sep 26.

PMID:
25263718
43.

Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.

Fernandez-Martos C, Brown G, Estevan R, Salud A, Montagut C, Maurel J, Safont MJ, Aparicio J, Feliu J, Vera R, Alonso V, Gallego J, Martin M, Pera M, Sierra E, Serra J, Delgado S, Roig JV, Santos J, Pericay C.

Oncologist. 2014 Oct;19(10):1042-3. doi: 10.1634/theoncologist.2014-0233. Epub 2014 Sep 10.

44.

Identification of ALK gene alterations in urothelial carcinoma.

Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE.

PLoS One. 2014 Aug 1;9(8):e103325. doi: 10.1371/journal.pone.0103325. eCollection 2014.

45.

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.

Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.

PMID:
25011934
46.

The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.

García-Alfonso P, Grande E, Polo E, Afonso R, Reina JJ, Jorge M, Campos JM, Martínez V, Angeles C, Montagut C.

Angiogenesis. 2014 Oct;17(4):805-21. doi: 10.1007/s10456-014-9433-6. Epub 2014 May 3. Review.

PMID:
24793846
47.

[Treatment of colorectal cancer with unresectable metastasis with chemotherapy without primary tumor resection: analysis of tumor-related complications].

Cáceres M, Pascual M, Alonso S, Montagut C, Gallén M, Courtier R, Gil MJ, Grande L, Andreu M, Pera M.

Cir Esp. 2014 Jan;92(1):30-7. doi: 10.1016/j.ciresp.2013.04.015. Epub 2013 Oct 28. Spanish.

PMID:
24176190
48.

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, Galan MC, Del Valle E, Vilardell F, Iglesias M, Fernandez S, Landolfi S, Cuatrecasas M, Mayorga M, Jose Paulés M, Sanz-Moncasi P, Montagut C, Garralda E, Rojo F, Hidalgo M, Lopez-Rios F.

J Clin Oncol. 2013 Dec 10;31(35):4445-52. doi: 10.1200/JCO.2013.48.9070. Epub 2013 Oct 14.

PMID:
24127447
49.

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12.

50.

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.

Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J.

Invest New Drugs. 2013 Apr;31(2):390-8. doi: 10.1007/s10637-012-9830-x. Epub 2012 May 22.

PMID:
22615059

Supplemental Content

Loading ...
Support Center